Supplementary Table 1. Newly acquired unpublished clinical data for cases previously described by our group

		Outcomes				nent	Details	Clinical Data		Molecular Data
Case	Reference	Overall Survival	PFS	Best Response	Chemo		Surgery	Demographics (Age, Sex)	Disease location/extent	NUT fusion partner
1	4			Χ	Х	Х	Х		X	
2	4			X	Х	Х	Х		X	
3	4			Χ	Х	Х	Х		X	
4	4			X	Х	Х	Х		X	
5	4			X	Х	Х	Х		X	
6	23	Х	Х	X	Х	Х	Х		X	
7	17	Х	Х	Х	Х	Х	Х	X	X	Х
8	17	Х	Х	Х	Х	Х	Х	Х	X	X
9	17	X	Х	Χ	Х	Х	Х	X	X	Х
10	17	Х	Х	X	Х	Х	X	X	X	X
11	17	Х	Х	X	Х	Х	Х	X	X	X
12	17							X	X	X
13	17	Х	Х	X	Х	Х	Х	X	X	X
14	17	Х	Х	X	Х	Х	Х	X	X	Х
15	17	Х	Х	X	Х	Х	X	X	X	Х
16	17	Χ	Х	X	Х	Х	X	X	X	Х
17	17							X	X	X
18	24									
19	8, 2									
20	8, 2									
21	18		Х	X	Х	Х	Х		X	
22	18									
23	18		Х	X	Х	Х	Х			
24	18		Х	X	Х	Х	X			
25	18		Х	X	Х	Х	X			
26	18		Х	X	Х	Х	X			
27	18		Х	X	Х	Х	Х			
28	18		Х	Х	Х	Х	Х			
29	6	Х	Х							
30	15	Х	Х							
31	3		X	Χ	Х	Х	Х		X	
32	13									
33	13									
34	12									
35	22	X	Х	X	Х	Х	Х		X	
35		13	21	24	24	24	24	11	20	11

X, new data which is presented in this manuscript, but was not present in the original publication; PFS, progression-free survival; Chemo, chemotherapy; RT, radiation therapy.